Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +45.01%
#2 Mubarak Mubarak +39.83%
#3 Pons Pons +37.09%
#4 Starpower Starpower +34.73%
#5 Bitway Bitway +34.69%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +31.89%
#7 TENDIES TENDIES +27.14%
#8 SkyAI SkyAI +25.15%
#9 Ocean Protocol Ocean Protocol +21.53%
#10 Decred Decred +19.54%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
SynCore Biotechnology Co.,Ltd SynCore Biotechnology Co.,Ltd

SynCore Biotechnology Co.,Ltd

4192
Clasificación en acciones #29314
SynCore Biotechnology Co.,Ltd, a Taiwan-based enterprise, specializes in the... SynCore Biotechnology Co.,Ltd, a Taiwan-based enterprise, specializes in the development and commercialization of biotechnology services, alongside offering expertise in food advisory and medicine inspection. The company's robust pipeline includes several promising drug candidates. Among its novel chemical entities (NCEs), SB01 is an injectable anti-cancer compound currently undergoing Phase II clinical trials for head and neck cancer. Another anti-cancer NCE, SB02, is in preclinical development, targeting stomach cancer. Beyond novel compounds, SynCore also markets established pharmaceutical solutions. This includes SB03-Veregen, an ointment prescribed for external genital and perianal warts. Its portfolio further extends to SB04, a conventional medication for age-related macular degeneration, presently in Phase II clinical studies. Additionally, SynCore is advancing SB05-EndoTAG, an established drug undergoing Phase III clinical trials for the treatment of both pancreatic cancer and triple-negative breast cancer. In a related venture, the company distributes epiCam brand cameras, which are designed for recording the progression of ophthalmic diseases. SynCore maintains strategic collaborations with notable entities such as Medigene AG, MacuCLEAR Inc., Sinphar Pharmaceutical Co., Ltd., and The National Health Research Institutes. Founded in 2008, SynCore Biotechnology Co.,Ltd is headquartered in Yilan City, Taiwan, and operates as a subsidiary of Sinphar Pharmaceutical Co., Ltd.
Precio por acción
$0.62008105
Última sincronización: 2026-08-18
Capitalización bursátil
$21.81M
Cambio (1 día)
0.26%
Cambio (1 año)
-31.95%
País
TW
Comercio SynCore Biotechnology Co.,Ltd (4192)

Categoría

Healthcare
Ganancias de SynCore Biotechnology Co.,Ltd (4192)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di SynCore Biotechnology Co.,Ltd, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de SynCore Biotechnology Co.,Ltd desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH